Skip to main content
Clinical Trials/CTRI/2020/02/023195
CTRI/2020/02/023195
Completed
Phase 4

Effect of Sodium-glucose Co-Transporter 2 (SGLT2) inhibitors of Left Ventricular Mass and Diastolic Function in Type-2 Diabetes Mellitus Patients at a Tertiary Care Hospital in South India.

izams Institute of Medical Sciences0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: E119- Type 2 diabetes mellitus without complications
Sponsor
izams Institute of Medical Sciences
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
izams Institute of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • 1\)Patients aged between 18 and 65 years of either sex.
  • 2\)Type 2 Diabetes Mellitus Patients with HbA1c \>\=7% \<\= 10%.
  • 3\. patients asymptomatic and without history of CVD.
  • 4\)Patients on stable dose of tablet metformin (1000\-2500mg) plus any 2 of the folloowing durg combinations\- tablet glimiperide (2\-8mg), tablet gliclazide SR 30\-80 mg, tablet linagliptin 5mg, tablet sitaglyptin 100mg, tablet vildagliptin 50mg, tablet tenaligliptin 20mg since last 3 months.
  • 5\)Patients who are SGLT2 inhibitor naïve.

Exclusion Criteria

  • 1\)Patients on insulin and GLP\-1 analogues
  • 2\)Patients with h/o type 1 Diabetes Mellitus, Congestive Cardiac Failure, Myocardial Infarction, Renal \& Hepatic impairment.
  • 3\)Pregnant women and lactating mothers
  • 4\)Patients not willing to give informed consent and comply with study related procedures.

Outcomes

Primary Outcomes

Not specified

Similar Trials